Rigel Pharmaceuticals RIGL Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Rigel Pharmaceuticals's change in accrued liabilities?
- Rigel Pharmaceuticals (RIGL) reported change in accrued liabilities of -$5.91M in Q1 2026.
- How has Rigel Pharmaceuticals's change in accrued liabilities changed year-over-year?
- Rigel Pharmaceuticals's change in accrued liabilities decreased by 43.5% year-over-year, from -$4.12M to -$5.91M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.